University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Consegna Pharma

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

Mental and Behavioral Health

Therapeutic Indications

Opioid overdose

Funding Stage

Seed

Founders

Larry Zana

Website

https://www.consegnapharma.com

Consegna Pharma is a Pittsburgh specialty pharmaceutical company that reformulates known, safe drugs into long-acting injectable medications with improved clinical and economic benefits. Its lead candidate, CP216, is a long-acting injectable naloxone designed to reverse an opioid overdose immediately and then release over 12 to 24 hours to prevent renarcotization. [1]

The company was founded in 2017 as a University of Pittsburgh spinout, with Larry Zana as founder, president, and CEO. In April 2022 it acquired Fathom Pharma, adding a pipeline of long-acting pain medicines. [2]

Discover More with AI